Grants(48)

A Phase 2, Randomized, Open-label Study of Onvansertib in Combination with FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-line Tre
Active·2024·$0 / $548.6K·
External
Co-Investigator (COI)
oncology, clinical trials, chemotherapy, cancer treatment, targeted therapy
Brightline-2: A Phase IIa/IIb, Open-label, Single-arm, Multi-centre Trial of BI 907828 for Treatment of Patients With Locally Advanced / Metastatic, MDM2 Amplified, TP53 Wild-type Biliary Track Adenoc
Active·2024·$1.8M / $462K·
External
Principal Investigator (PI)
cancer treatment, clinical trial, biliary tract adenocarcinoma, targeted therapy, precision medicine
A Phase 2a, Double-Blind, Placebo-Controlled, Multi-Center, Randomized Study Evaluating LSTA1 when Added to Standard of Care (SOC) Versus Standard of Care Alone in Subjects with Advanced Solid Tumors
Active·2023·$6.6M / $825.5K·
External
Principal Investigator (PI)
oncology, clinical trials, immunotherapy, cancer treatment, drug efficacy
A Phase 1 Dose-Escalation Study of FF-10832 for the Treatment of Advanced Solid Tumors and Lymphomas
Active·2023·$6.2M / $684.8K·
External
Principal Investigator (PI)
cancer treatment, drug trial, dose escalation, solid tumors, lymphomas
Randomized Phase 2 Study of DKN-01 Plus FOLFIRI/FOLFOX and Bevacizumab Versus FOLFIRI/FOLFOX and Bevacizumab as Second-line Treatment of Advanced Colorectal Cancer (DeFianCe)
Active·2023·$0 / $568.2K·
External
Co-Investigator (COI)
colorectal cancer, treatment, clinical trial, dkn-01, chemotherapy

Page 1 of 10

People

Profile

Rachna Shroff

Collaboration(44)

Terry Badger

Denise Roe

Linda Garland

Chris Segrin

Megha Padi

Grants(48)

A Phase 2, Randomized, Open-label Study of Onvansertib in Combination with FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-line Tre

Brightline-2: A Phase IIa/IIb, Open-label, Single-arm, Multi-centre Trial of BI 907828 for Treatment of Patients With Locally Advanced / Metastatic, MDM2 Amplified, TP53 Wild-type Biliary Track Adenoc

A Phase 2a, Double-Blind, Placebo-Controlled, Multi-Center, Randomized Study Evaluating LSTA1 when Added to Standard of Care (SOC) Versus Standard of Care Alone in Subjects with Advanced Solid Tumors

A Phase 1 Dose-Escalation Study of FF-10832 for the Treatment of Advanced Solid Tumors and Lymphomas

Randomized Phase 2 Study of DKN-01 Plus FOLFIRI/FOLFOX and Bevacizumab Versus FOLFIRI/FOLFOX and Bevacizumab as Second-line Treatment of Advanced Colorectal Cancer (DeFianCe)

Publications(191)

The room where it happens: addressing diversity, equity, and inclusion in National Clinical Trials Network clinical trial leadership

Reply: Living donor liver transplantation for people with PSC

Multiomic Characterization Reveals a Distinct Molecular Landscape in Young-Onset Pancreatic Cancer

Reply: insurance should cover vancomycin for primary sclerosing cholangitis

Independent of Primary Sclerosing Cholangitis and Cirrhosis, Early Adulthood Obesity Is Associated with Cholangiocarcinoma

An adaptive approach to neoadjuvant therapy to maximize resection rates for pancreatic adenocarcinoma: A phase II trial.

Comparative Genomic Analysis of Pancreatic Acinar Cell Carcinoma PACC) and Pancreatic Ductal Adenocarcinoma PDAC) Unveils New Actionable Genomic Aberrations in PACC

The Cholangiocarcinoma in the Young CITY) Study: Tumor Biology, Treatment Patterns, and Survival Outcomes in Adolescent Young Adults With Cholangiocarcinoma

Molecular profiling and treatment pattern differences between intrahepatic and extrahepatic cholangiocarcinoma

Liver-Directed Therapy Combined with Systemic Therapy: Current Status and Future Directions